Short sellers have quietly doubled down on DD in recent weeks — and the timing, three days before the May 21 earnings release, makes the move worth watching.
The most striking signal is the pace of short-interest accumulation. Short interest in DuPont has climbed 25% over the past week alone, reaching 3.0% of the free float. Over the past month the position has grown by roughly 64%. That is a meaningful acceleration from a base that was sitting near 1.8% as recently as early April. The ORTEX short score has ticked up each session this week, reaching 36.5 — still moderate in absolute terms, but the direction of travel is clearly higher. Options positioning adds a layer of caution: the put/call ratio has climbed to 0.55, nearly two standard deviations above its 20-day average of 0.48, suggesting more demand for downside protection than usual heading into the print. The borrow market, however, remains relaxed. Cost to borrow eased to 0.38% from above 0.51% earlier in the month, and availability is ample, meaning the short-side build reflects deliberate conviction rather than a squeeze-driven scramble.
The stock itself sits at $49.31, down about 2.5% on Friday and roughly flat on the week after a 5.6% one-month rebound. That recovery has stalled just below the mean analyst price target of $57.07, which implies around 16% upside from current levels. The analyst community is cautiously constructive: RBC raised its target to $60 last week while keeping Outperform, and UBS lifted to $59 following the prior earnings beat. B of A Securities is the outlier, sitting at Neutral with a $47 target — below where the stock is trading now. The bulls point to high-single-digit growth in Healthcare and Water, and the company's stated ambition to lift the vitality index (share of revenue from newer products) to 45%. Bears flag ongoing weakness in electronics and construction markets, sluggish China recovery, and execution risk around the post-merger portfolio.
The insider angle adds a wrinkle. On May 4, five executives — including CEO Lori Koch, Executive Chairman Edward Breen, and CFO Antonella Franzen — all filed sales at $45.54. The transactions were small in dollar terms and low in significance scores, likely tied to scheduled equity-plan exercises. But a broad cluster of C-suite sales at prices below the current close and well below the analyst target is a data point that sits awkwardly alongside the bullish setup. The 90-day net insider flow is marginally positive at around 55,000 shares, so the picture is not definitively negative, but the directional signal from management is muted at best.
The May 21 print will test whether DuPont's Healthcare and Water momentum is strong enough to offset continued drag from its cyclically exposed segments — and whether the recent short-side accumulation reflects informed caution or a position that gets squeezed if the numbers hold up.
See the live data behind this article on ORTEX.
Open DD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
